Glenmark recalls 15 lakh bottles of ADHD medication in US: USFDA

Glenmark Pharmaceuticals is recalling around 14.76 lakh bottles of Atomoxetine Capsules due to detected CGMP deviations and the presence of N-Nitroso Atomoxetine impurity above FDA recommended limits. The recall is classified as Class II, indicating potential temporary or medically reversible adverse health consequences.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T3ZxXRF
via IFTTT